*AbbVie, InterMune say they defending business secrets. The decision leaves in limbo a high-profile fight that has pitched the European Medicines Agency, Europe's equivalent of the U.S. Food and Drug Administration, against AbbVie and InterMune.» Read More
WASHINGTON-- Specialty drugmaker Celgene Corp. said Friday a panel of European Union medical experts issued a positive review of its drug Abraxane for patients with late-stage pancreatic cancer. The U.S. Food and Drug Administration approved Celgene's drug for late-stage pancreatic cancer in September.
*Ontario ban could be imitated by other provinces. Pharmacy companies saw the private-label drugs as a way to reduce the impact of Ontario regulations designed to lower the cost of generic drugs. The Ontario rules have weighed on the earnings of the drugstore chains, including Shoppers Drug Mart Corp, a principal appellant in this case.
WASHINGTON-- Shares of Biogen Idec jumped to an all-time high Friday morning after the company said European regulators have determined its new multiple sclerosis is a novel drug, granting it 10 years of market exclusivity in the European Union.
LONDON, Nov 22- European shares opened higher on Friday, lifted by Swiss drugmaker Novartis after a $5 billion share buyback announcement, with sentiment also supported by rallies in U.S. and Japanese shares overnight.
ZURICH, Nov 22- Swiss drugmaker Novartis offered a sweetener to investors on Friday by starting a $5 billion share buyback programme, but shied away from announcing any radical surgery to its structure.
Carl Berg, billionaire venture capitalist and co-founder, Berg and Berg, sees huge opportunities in life sciences. Berg Pharma has the opportunity to revolutionize health care by using biology to determine differences between a healthy and unhealthy person.
New York- based JLL will merge the DSM business with that of Toronto- based drug maker Patheon Inc, forming a joint venture boasting some $2 billion in annual sales that the companies said on Tuesday will be a leader in manufacturing medicines for pharmaceutical companies.
Stefan Dobocky, board member at DSM, says that by merging its pharma division with drug maker Patheon, a "global leader" will be created, and explains that the new entity will be run as a separate company.
NEW YORK, Nov 19- PharMEDium Services LLC, a venture capital-backed provider of pharmacy compounding services to hospitals, is in discussions to sell itself for close to $1 billion, according to people familiar with the matter.
Spending on expensive new specialty drugs for cancer and other ailments will rise to between $230 billion and $240 billion by 2017, up 38 percent from $171 billion last year, the report from the IMS Institute for Healthcare Informatics, a division of healthcare information company IMS Health, said.
AMSTERDAM, Nov 19- Dutch food and chemicals group DSM said on Tuesday it was spinning off its pharmaceuticals division in a $2.6 billion deal with private equity firm JLL, pushing DSM's shares up more than 3 percent. JLL is the majority shareholder in contract drug maker Patheon.
*Diet drugs and plans a hard sell, despite rising obesity. KALUNDBORG, Denmark, Nov 14- Steam rises from pipes at a giant industrial complex on the edge of the Baltic Sea whose success is a testament to the world's diabetes and obesity epidemic.
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.
Amazon.com is clashing with Johnson & Johnson amid complaints the online retailer hasn't stopped sales of damaged or expired products.
*Grifols shares up 2.3 percent, Novartis adds 0.5 percent. ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion testing unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for healthcare deals.
ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion diagnostics unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for pharmaceutical mergers and acquisitions.
FRANKFURT, Nov 8- Germany's Boehringer Ingelheim, the world's largest unlisted drugmaker, is looking to expand its animal health business and is set to make an offer for poultry vaccine and feed additives maker Lohmann, two people familiar with the matter said.
Nov 7- Bristol-Myers Squibb Co said on Thursday that it would no longer conduct research to discover new drugs for hepatitis C, diabetes and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer.